The lancet oncology
-
The lancet oncology · Dec 2024
Comparative StudyEffectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
Black patients were severely under-represented in the clinical trials that led to the approval of immune checkpoint inhibitors (ICIs) for all cancers. The aim of this study was to characterise the effectiveness and safety of ICIs in Black patients. ⋯ Million Veteran Program, Office of Research and Development, Veterans Health Administration and the LUNGevity foundation.
-
The lancet oncology · Dec 2024
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis.
Recommendations by countries' health technology assessment (HTA) agencies are used to decide which new therapies warrant the allocation of limited health-care resources to make them available through publicly funded health systems. This process is of public health importance for balancing the dual aims of optimising patient outcomes while ensuring financial sustainability. We evaluated which factors affect HTA outcomes and the time to positive HTA outcome, focussing on the role of clinical benefit evaluated with the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). ⋯ None.
-
The lancet oncology · Dec 2024
Observational StudyPreferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment.
The extent to which patients with cancer are willing to accept uncertainty about the clinical benefit of new cancer drugs in exchange for faster access is not known. This study aims to examine preferences for access versus certainty, and to understand factors that influence these preferences. ⋯ The London School of Economics and Political Science Phelan United States Centre.
-
The lancet oncology · Dec 2024
The current and future global burden of cancer among adolescents and young adults: a population-based study.
Compared with children and older adults, the burden of cancer in adolescents and young adults (ages 15-39) is understudied. We aimed to quantify the global burden of adolescent and young adult cancer in 2022 and 2050, and explore patterns in incidence, mortality, and case fatality. ⋯ None.